InsidersTradesSigma
Innovent Biologics, Inc. Stock: price and management transactions · Hong Kong · HKEX
Follow the Innovent Biologics, Inc. share price and the full insider trade history of the company, a listed equity based in Hong Kong. Shares trade on HK HK, under the supervision of HKEX. Operating in the Health Care sector, Innovent Biologics, Inc. has recorded 16 reports. Market capitalisation: €157.8bn. The latest transaction was reported on 9 July 2026 (Sale). Among the most active insiders: Ede Ronald Hao Xi. The full history is free.
16
Insider Decl.
0
Thresholds
·
8 ops.
Buy Volume
€58m
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Innovent Biologics, Inc. Strong Buy (bullish), based on 25 analysts. Average price target: HK$116.99.
31Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 10,665 of 26,213 companies
56.7
score / 100
Value52
Quality62
FCF yld5.9%
Earn yld0.5%
EV/EBITDA·
ROE5.0%
Gross mgn87%
Net mgn6.2%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 July 2026
Declarations16 total
752,381 shares@ €9.88150.042% mcap16.7% of flowShareXHKGHKEX:DA20260708E00744
752,381 sharesShareXHKGHKEX:DA20260708E00743
1,882,334 shares@ €9.76990.10% mcap41.3% of flowShareXHKGHKEX:DA20260708E00742
1,882,334 sharesShareXHKGHKEX:DA20260708E00741
43,431 shares@ €9.61630.0003% mcap100.0% of flowShareXHKGHKEX:DA20260519E00088
1,352,952 shares@ €9.68730.075% mcap100.0% of flowShareXHKGHKEX:DA20260512E00541
24,226 sharesShareXHKGHKEX:DA20260402E00009
Ideal exit: 25 Dec 2026 (T+270)
24,226 sharesShareXHKGHKEX:DA20260402E00005
Ideal exit: 25 Dec 2026 (T+270)
225,000 sharesShareXHKGHKEX:DA20260402E00002
Ideal exit: 25 Dec 2026 (T+270)
24,226 sharesShareXHKGHKEX:DA20260402E00006
Ideal exit: 25 Dec 2026 (T+270)
24,226 sharesShareXHKGHKEX:DA20260402E00010
Ideal exit: 25 Dec 2026 (T+270)
1,863,000 sharesShareXHKGHKEX:DA20260402E00003
Ideal exit: 25 Dec 2026 (T+270)
330,000 sharesShareXHKGHKEX:DA20260402E00008
Ideal exit: 25 Dec 2026 (T+270)
39,366 sharesShareXHKGHKEX:DA20260402E00007
Ideal exit: 25 Dec 2026 (T+270)
1,000,000 shares@ €9.46480.0068% mcap50.5% of flowShareXHKGHKEX:DA20260402E00001
986,000 shares@ €9.41380.0067% mcap49.5% of flowShareXHKGHKEX:DA20260401E00593
16 of 16 declarations
About Innovent Biologics, Inc.
Innovent Biologics, Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of cancer and other diseases. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.